Prognostic significance of Bax and Fas Ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma

被引:18
|
作者
Kokturk, N
Firat, P
Akay, H
Kadilar, C
Ozturk, C
Zorlu, F
Gungen, Y
Emri, S
机构
[1] Gazi Univ, Sch Med, Dept Pulm Med, Ankara, Turkey
[2] Hacettepe Univ, Sch Med, Dept Pathol, TR-06100 Ankara, Turkey
[3] Ankara Univ, Sch Med, Dept Thorac Surg, TR-06100 Ankara, Turkey
[4] Hacettepe Univ, Sch Med, Dept Stat, TR-06100 Ankara, Turkey
[5] Hacettepe Univ, Sch Med, Dept Radiat Oncol, TR-06100 Ankara, Turkey
[6] Hacettepe Univ, Sch Med, Dept Pulm Med, TR-06100 Ankara, Turkey
关键词
mesothelioma; erionite; asbestos; apoptosis; Bax; Fas Ligand;
D O I
10.1016/j.lungcan.2005.05.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Environmentally exposed erionite is a potent and unique inducer of malignant pleural mesothelioma (MPM) in Central Anatolia in Turkey. Previous studies have shown that erionite induced MPM has different biological behavior than asbestos induced MPM. Although impaired apoptosis has been implicated in tumor biology, the relationship between the type of environmental exposure and apoptosis has not yet been evaluated in MPM. The purpose of this study was to determine the expression of apoptosis regulating proteins and their prognostic significance in erionite and asbestos induced MPM. Thirty-five patients with MPM (16 erionite and 19 asbestos induced), and 17 patients with adenocarcinoma were comparatively evaluated. Expression of Bcl-2, Bax, Fas and Fas Ligand, were assessed by immunohistochemistry. Bcl-2 and Fas did not stain in almost all specimens. The staining extension of Bax was 13.75 +/- 19.27%, 5.89 +/- 14.51% and 7.38 +/- 14.53% for erionite and asbestos induced MPM and adenocarcinoma, respectively (p = 0.566). The staining extension of Fas Ligand was 26.87 +/- 31.87%, 46.10 +/- 37.30% and 26.47 +/- 23.23% for erionite and asbestos induced MPM, and adenocarcinoma, respectively (p = 0.123). Bax negative patients in erionite group had longer survival than Bax positive patients (18 months versus 14 months) (p = 0.06). Fas Ligand positive patients showed statistically better survival than Fas Ligand negative patients in all MPM group (15 months versus 12 months) (p = 0.05). Although all proteins expressed in similar extension in all samples, Bax staining displayed an inverse relation with survival in erionite group. This may implicate a difference in Bax functioning in erionite induced MPM. However, Fas Ligand may be functionally intact to reduce tumor survival. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:189 / 198
页数:10
相关论文
共 50 条
  • [31] Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos
    Magnani, C
    Agudo, A
    González, CA
    Andrion, A
    Calleja, A
    Chellini, E
    Dalmasso, P
    Escolar, A
    Hernandez, S
    Ivaldi, C
    Mirabelli, D
    Ramirez, J
    Turuguet, D
    Usel, M
    Terracini, B
    BRITISH JOURNAL OF CANCER, 2000, 83 (01) : 104 - 111
  • [32] Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey
    Karakoca, Y
    Emri, S
    Bagci, T
    Demir, A
    Erdem, Y
    Baris, E
    Sahin, AA
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1998, 2 (12) : 1017 - 1022
  • [33] Asbestos Exposure in Patients with Malignant Pleural Mesothelioma included in the PRIMATE Study, Lombardy, Italy
    Spinazze, Andrea
    Consonni, Dario
    Borghi, Francesca
    Rovelli, Sabrina
    Cattaneo, Andrea
    Zellino, Carolina
    Dallari, Barbara
    Pesatori, Angela Cecilia
    Kromhout, Hans
    Peters, Susan
    Riboldi, Luciano
    Cavallo, Domenico Maria
    Mensi, Carolina
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (06)
  • [34] Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed
    Takeuchi, Susumu
    Seike, Masahiro
    Noro, Rintaro
    Soeno, Chie
    Sugano, Teppei
    Zou, Fenfei
    Uesaka, Haruka
    Nishijima, Nobuhiko
    Matsumoto, Masaru
    Minegishi, Yuji
    Kubota, Kaoru
    Gemma, Akihiko
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (06) : 1886 - 1894
  • [35] Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion
    Kato, Katsuya
    Gemba, Kenichi
    Fujimoto, Nobukazu
    Aoe, Keisuke
    Takeshima, Yukio
    Inai, Kouki
    Kishimoto, Takumi
    EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (09) : 1594 - 1600
  • [36] Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma
    Creaney, Jenette
    Dick, Ian M.
    Segal, Amanda
    Musk, Arthur W.
    Robinson, Bruce W. S.
    LUNG CANCER, 2013, 82 (03) : 491 - 498
  • [37] Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
    Fujimoto, Nobukazu
    Ohnuma, Kei
    Aoe, Keisuke
    Hosono, Osamu
    Yamada, Taketo
    Kishimoto, Takumi
    Morimoto, Chikao
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S200 - S200
  • [38] Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers
    Creaney, Jenette
    Dick, Ian M.
    Musk, A. W.
    Olsen, Nola J.
    Robinson, Bruce W. S.
    BIOMARKERS, 2016, 21 (06) : 551 - 561
  • [39] Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma
    Hirayama, Noriko
    Tabata, Chiharu
    Tabata, Rie
    Maeda, Risa
    Yasumitsu, Akihiro
    Yamada, Shusai
    Kuribayashi, Kozo
    Fukuoka, Kazuya
    Nakano, Takashi
    RESPIRATORY MEDICINE, 2011, 105 (01) : 137 - 142
  • [40] Prognostic Biomarkers for Malignant Pleural Mesothelioma Treated with Chemotherapy
    Akgun, Hakan
    Metintas, Selma
    Ak, Guntulu
    Demirkol, Secil
    Aydin, Resat
    Isbilen, Murat
    Gure, Ali
    Metintas, Muzaffer
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1369 - S1369